公开(公告)号：US20240360220A1

公开(公告)日：2024-10-31

申请号：US18647843

申请日：2024-04-26

申请人： Xencor, Inc.

发明人： Gregory Moore ,  John R. Desjarlais ,  Bhavika R. Patel

IPC分类号： C07K16/28

CPC分类号： C07K16/283 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55

摘要： Provided herein are multimeric proteins that reduce the promiscuous pairing of monomers of the multimeric protein and/or promote the proper pairing of monomers of the multimeric proteins, as well as methods of using such multimeric proteins.

公开(公告)号：US12129309B2

公开(公告)日：2024-10-29

申请号：US17736475

申请日：2022-05-04

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal

IPC分类号： C07K16/40 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/40 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/3061 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

公开(公告)号：US20240279317A1

公开(公告)日：2024-08-22

申请号：US18414799

申请日：2024-01-17

申请人： Allergan, Inc. ,  Xencor, Inc.

发明人： Peter C. Baciu ,  Yanbin LIANG ,  Jason Guu ,  Matthew Bernett ,  Umesh Muchhal ,  John Desjarlais

IPC分类号： C07K16/18 ,  A61K39/00 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/3955 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.

公开(公告)号：US20240262907A1

公开(公告)日：2024-08-08

申请号：US18248030

申请日：2021-10-06

申请人： Xencor, Inc.

发明人： Ying DING ,  John R. DESJARLAIS ,  Bart BURINGTON ,  Raphael CLYNES ,  Debra J. ZACK ,  Paul FOSTER ,  Joel GUTHRIDGE

IPC分类号： C07K16/28 ,  A61P37/06 ,  G01N33/564

CPC分类号： C07K16/2803 ,  A61P37/06 ,  G01N33/564 ,  C07K2317/31 ,  G01N2800/104 ,  G01N2800/52

摘要： The disclosure relates to methods of detecting one or more biomarkers. and/or treating autoimmune diseases such as systemic lupus erythematous (SLE) with an anti-CD19 antibody based on the presence of such biomarkers. The biomarkers can be separate or in combination, and their detection can be used in multiple different methods.

公开(公告)号：US12054545B2

公开(公告)日：2024-08-06

申请号：US17542341

申请日：2021-12-03

申请人： Xencor, Inc.

发明人： Gregory Moore ,  Rumana Rashid ,  Sung-Hyung Lee ,  Paul Foster

IPC分类号： A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2809 ,  A61P35/00 ,  C07K16/2869 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73

摘要： The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).

公开(公告)号：US20240166705A1

公开(公告)日：2024-05-23

申请号：US18503935

申请日：2023-11-07

申请人： Xencor, Inc.

发明人： Alex NISTHAL ,  John DESJARLAIS ,  Gregory MOORE ,  Sung-Hyung LEE ,  Matthew Adam DRAGOVICH

IPC分类号： C07K14/54 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K14/54 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/30

摘要： Provided herein are variant human IL18 proteins including proteins and constructs including such. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or improve production yield are also described. Also provided are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain. Also provided herein are IL18Fc fusion proteins that bind CD3 and a tumor target antigen.

公开(公告)号：US20240150471A1

公开(公告)日：2024-05-09

申请号：US18502668

申请日：2023-11-06

申请人： Xencor, Inc.

发明人： Matthew S. Faber

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/2851 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/732

摘要： Described herein are antibodies, including multispecific antibodies, that bind to NK cells, optionally a tumor target antigen (TTA) and have increased binding to the CD16A receptor. The antibodies can include an NK cell antigen binding domain (ABD) that binds to the extracellular domain of an NK cell antigen such as NKG2D, NKp30, and NKp46.

公开(公告)号：US11945880B2

公开(公告)日：2024-04-02

申请号：US17542342

申请日：2021-12-03

申请人： Xencor, Inc.

发明人： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC分类号： C07K16/30 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

CPC分类号： C07K16/468 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US11919958B2

公开(公告)日：2024-03-05

申请号：US17407135

申请日：2021-08-19

申请人： Xencor, Inc.

发明人： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng

IPC分类号： C07K16/28

CPC分类号： C07K16/2827 ,  C07K16/2818 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622

摘要： Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

公开(公告)号：US11919956B2

公开(公告)日：2024-03-05

申请号：US17321325

申请日：2021-05-14

申请人： Xencor, Inc.

发明人： John R. Desjarlais ,  Alex Nisthal ,  Michael Hedvat ,  Matthew Adam Dragovich

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C12N15/63

CPC分类号： C07K16/2809 ,  A61P35/00 ,  C07K16/3069 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/73

摘要： Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.